The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report

Ahmed Badran; Clara Steele; Hisham Alquaydheb; Ahmed Ba Theeb; Abdulmalik Bawazir; Mahmoud A Elshenawy; Jean Paul Atallah

doi:10.1159/000532099

The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report

Case Rep Oncol. 2023 Aug 28;16(1):746-752. doi: 10.1159/000532099. eCollection 2023 Jan-Dec.

Authors

Ahmed Badran^{1

2}, Clara Steele³, Hisham Alquaydheb⁴, Ahmed Ba Theeb⁵, Abdulmalik Bawazir⁵, Mahmoud A Elshenawy^{1

6}, Jean Paul Atallah¹

Affiliations

¹ Department of Medical Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
² Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
³ School of Medicine, Brookfield Health Sciences Complex, University College Cork, Cork, Ireland.
⁴ Department of Internal Medicine, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.
⁵ Faculty of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
⁶ Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Menoufia University, Shebin El Kom, Egypt.

Abstract

Sclerosing epithelioid fibrosarcoma is an ultra-rare and aggressive high-grade fibrosarcoma that was originally described in 1995. More than 100 cases are documented worldwide, with the most extensive case series reporting a high rate of recurrence and metastasis. ALK mutations are commonly seen in soft-tissue sarcomas; however, this is the first known case of an ALK V757M mutation. Here, we present a case using crizotinib in treating an ALK-positive sclerosing epithelioid fibrosarcoma refractory to all traditional treatment options.

Keywords: Anaplastic lymphoma kinase mutation; Crizotinib; Sclerosing epithelioid fibrosarcoma.

Publication types

Case Reports